MAGIC Ruxolitinib for aGVHD

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(14 sites)

United States

City of Hope Comprehensive Cancer Center, Duarte, California

Moffitt Cancer Center, Tampa, Florida

Winship Cancer Institute, Emory University, Atlanta, Georgia

Kansas University Medical Center, Fairway, Kansas

Massachusetts General Hospital, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Mayo Clinic, Rochester, Minnesota

Washington University, St Louis, Missouri

Icahn School of Medicine at Mount Sinai, New York, New York

Ohio State University, Columbus, Ohio

University of Pennsylvania, Philadelphia, Pennsylvania

Vanderbilt University, Nashville, Tennessee

MD Anderson Cancer Center, Houston, Texas

Fred Hutchinson Cancer Research Center, Seattle, Washington